by GlobeNewsWire | Sep 6, 2016 | Globe Newswire
PRINCETON, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O’Connor, president and chief executive officer of Advaxis, will present a...
by GlobeNewsWire | Aug 19, 2016 | Globe Newswire
Kim Dorney to give opening keynote to cervical cancer survivors PRINCETON, N.J., Aug. 19, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS) a clinical-stage biotechnology company developing cancer immunotherapies, is pleased to participate in Cervivor School...
by GlobeNewsWire | Aug 16, 2016 | Globe Newswire
PRINCETON, N.J., Aug. 16, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare...
by GlobeNewsWire | Jul 26, 2016 | Globe Newswire
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancerPRINCETON, N.J., July 26, 2016 (GLOBE NEWSWIRE) — Advaxis,...
by GlobeNewsWire | Jul 21, 2016 | Globe Newswire
PRINCETON, N.J., July 21, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead...